Fig. 5From: Alterations in the glycome after HDAC inhibition impact oncogenic potential in epigenetically plastic SW13 cellsHDAC inhibitor treatment promotes paclitaxel resistance in SW13 cells. SW13 cells were left untreated (Control), or were treated with 1 nM FK228 for 24 h (FK228). After, 24 h, FK228 was removed, and control SW13 cells and FK228 pre-treated cells were plated into 96 well plates and left untreated (Control), or were treated with 1 nM, 10 nM, or 50 nM paclitaxel for (a) 24 h or (b) 48 h. Cell viability was assessed using an MTT assay. Data are presented as means ± SEM, and are representative of three independent experiments. Superscripts denote statistical significance, p < 0.05. Treatments that share the same superscripts are not significantly differentBack to article page